MannKind Sold A 1% Royalty In Net Sales Of Tyvaso DPI (Treprostinil) Inhalation Powder In Exchange For Up To $200M, Including The Purchase Price Of $150M And An Additional Potential Milestone Payment Of Up To $50M
Portfolio Pulse from Benzinga Newsdesk
MannKind Corporation has entered into a deal to sell a 1% royalty on net sales of Tyvaso DPI, a treprostinil inhalation powder, for up to $200 million. This includes an upfront purchase price of $150 million and an additional potential milestone payment of up to $50 million.
January 02, 2024 | 11:10 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
MannKind Corporation has sold a 1% royalty in net sales of Tyvaso DPI for a total deal value of up to $200 million, bolstering its financial position.
The sale of the royalty is likely to be viewed positively by investors as it provides MannKind with a significant cash infusion, which can be used to fund operations, reduce debt, or invest in further development. The upfront payment of $150 million is a substantial amount for the company, and the additional milestone payments could provide further financial benefits. This deal may increase investor confidence in MannKind's financial stability and its ability to generate revenue from its products.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100